‘For these…’: Kiran Mazumdar Shaw sounds warning as Nithin Kamath flags weak GLP 1 demand
India’s weight-loss drug increase will not be unfolding the best way many anticipated. As cheaper generic GLP-1 medicines enter the market, one in all India’s high entrepreneurs says demand is falling wanting expectations, whereas one of many nation’s main biotech pioneers is urging warning over their widespread use amongst in any other case wholesome individuals.
The controversy gathered momentum after Zerodha Co-founder Nithin Kamath highlighted what he described as a stunning slowdown within the adoption of generic GLP-1 medication in India.
His observations, shared on X, prompted a response from Biocon Govt Chairperson Kiran Mazumdar-Shaw, who careworn that way of life modifications ought to stay the primary line of therapy for people who find themselves neither diabetic nor clinically overweight.
Retention, not affordability, would be the greatest hurdle
Sharing his views on X whereas reposting a information report about waning enthusiasm surrounding GLP-1 gross sales, Kamath described India as “a bizarre market.”
MUST READ | As GLP-1 increase fades, Zerodha’s Nithin Kamath calls India a ‘bizarre market’
With weight problems charges rising, he mentioned he had anticipated demand for generic GLP-1 medicines to surge after patent expiries. Priced at round Rs 1,000-2,500 a month, he argued that the medication at the moment are cheaper than many gymnasium memberships. He additionally pointed to rising proof suggesting advantages past weight reduction, together with enhancements in cardiovascular, metabolic and liver well being.
But, in accordance with Kamath, generic drugmakers have quietly lowered their gross sales targets by 25-30%, signalling that shopper demand has not matched business expectations.
Mazumdar-Shaw urges lifestyle-first method
Responding to Kamath’s publish, Mazumdar-Shaw careworn that GLP-1 medication mustn’t grow to be the default selection for weight administration amongst wholesome people.
“For individuals who will not be diabetic or clinically overweight, food plan and train needs to be the primary possibility,” she wrote on X.
She additionally cautioned that GLP-1 therapies alter metabolic operate and contain neurological signalling, elevating questions on their long-term impression. “There may be not a lot long-term knowledge on persistent use of GLP-1s,” she famous, suggesting that larger warning is warranted earlier than embracing widespread use.
Why aren’t Indians embracing GLP-1 medication?
Kamath believes affordability is not the most important impediment.
As an alternative, he argued that retention is proving to be the actual problem. Since GLP-1 medicines are injectable therapies that typically require continued use, many sufferers regain weight after discontinuing therapy.
Based on him, convincing individuals to stay on a weekly injection indefinitely is proving to be a a lot tougher proposition than anticipated.
He additionally urged that Indian medical doctors could also be extra conservative in prescribing newer medicines than their Western counterparts. One other deterrent, he mentioned, is the discomfort related to self-administering injections, which can discourage many potential customers from beginning therapy.
Kamath mentioned the provision of oral GLP-1 tablets might alter the adoption curve by eradicating one of many greatest limitations — the necessity for normal injections.
